

ESPS Peer-review Report

Name of Journal: World Journal of Hepatology

ESPS Manuscript NO: 6767

Title: An update on Inflammatory Bowel Disease in patients with Primary Sclerosing Cholangitis

Reviewer code: 00049305

Science editor: Song, Xiu-Xia

Date sent for review: 2013-10-30 09:35

Date reviewed: 2013-12-08 18:55

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input checked="" type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	language polishing	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

In this review paper, Dr. Tsaitas, et al. described the clinical and molecular characteristics of PSC complicated by IBD. It presented the detailed information on the prevalence of this kind disorder, strategies for surveillance and treatment. 1, Please describe the genetic susceptibility of two kinds of disorders. 2, Please describe immuno-pathogenic links between two diseases. 3, In last sentence of Abstract, the authors mentioned the dose of UDCA at low doses (8-15 mg/dl) and high doses (15-30 mg/dl). Please check "mg/dl", it it correct? 4, Please describe how to differentially diagnose.